Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

422 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Depression and degree of acceptance of adjuvant cytotoxic drugs.
Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Colleoni M, et al. Among authors: mandala m. Lancet. 2000 Oct 14;356(9238):1326-7. doi: 10.1016/S0140-6736(00)02821-X. Lancet. 2000. PMID: 11073026
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Shitara K, et al. Among authors: mandala m. Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. Lancet. 2018. PMID: 29880231 Clinical Trial.
Locally advanced breast cancer.
Barni S, Mandalà M. Barni S, et al. Among authors: mandala m. Curr Opin Obstet Gynecol. 2006 Feb;18(1):47-52. doi: 10.1097/01.gco.0000192998.04793.ba. Curr Opin Obstet Gynecol. 2006. PMID: 16493260 Review.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Dummer R, et al. Among authors: mandala m. Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Lancet Oncol. 2018. PMID: 30219628 Clinical Trial.
Nras in melanoma: targeting the undruggable target.
Mandalà M, Merelli B, Massi D. Mandalà M, et al. Crit Rev Oncol Hematol. 2014 Nov;92(2):107-22. doi: 10.1016/j.critrevonc.2014.05.005. Epub 2014 Jun 12. Crit Rev Oncol Hematol. 2014. PMID: 24985059 Review.
422 results